Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Aug 8;15(8):e43138.
doi: 10.7759/cureus.43138. eCollection 2023 Aug.

FIP1L1-PDGFRA Clonal Hypereosinophilic Syndrome With Eosinophilic Myocarditis and Intracardiac Thrombus

Affiliations
Case Reports

FIP1L1-PDGFRA Clonal Hypereosinophilic Syndrome With Eosinophilic Myocarditis and Intracardiac Thrombus

Margaret Locke et al. Cureus. .

Abstract

A 45-year-old man from El Salvador with no past medical history presented with cough and chest pain. Investigations revealed 60% peripheral eosinophilia (absolute count 12.3 K/uL). Cardiac imaging was consistent with myocarditis with intracardiac thrombus formation. Endomyocardial biopsy confirmed eosinophilic infiltration of the myocardium, and bone marrow biopsy showed hypercellular marrow with 28% eosinophils. Cytogenetics/fluorescence in situ hybridization (FISH) confirmed positive FIP1L1-PDGFRA rearrangement. The patient was treated for FIP1L1-PDGFRA clonal hypereosinophilic syndrome with associated eosinophilic myocarditis and intracardiac thrombus. The treatment regimen consisted of a steroid taper, imatinib, and anticoagulation. Treatment was followed by normalization of the eosinophil count. At two-year follow-up, the patient was without recurrence of eosinophilia on maintenance imatinib and indefinite anticoagulation with warfarin.

Keywords: clonal hypereosinophilic syndrome; eosinophilic leukemia; eosinophilic myocarditis; hypereosinophilic syndrome; intracardiac thrombus.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. CT abdomen/pelvis with contrast showing splenomegaly (green line).
Figure 2
Figure 2. Four-chamber transthoracic echocardiogram showing mild left ventricular hypertrophy.
Figure 3
Figure 3. Phase-sensitive inversion recovery (PSIR) MRI image showing a layer of thrombus overlaying the lateral left ventricle.
Figure 4
Figure 4. a) Full-thickness section of the right ventricle wall including the endocardium (to left), myocardium, and epicardial fat surfaced by the mesothelium and containing a hemorrhage (to right), showing a collection of leukocytes, including numerous eosinophils at the myocardial-epicardial interface and extending into the myocardium and epicardial fat. Hematoxylin and eosin (H&E), 20x. b) Higher-magnification view of image 1 showing a collection of leukocytes, including numerous eosinophils at the myocardial-epicardial interface. H&E, 200x. c) Myocardium with eosinophils throughout the interstitium. H&E, 200x. d) Myocardium with eosinophils throughout the interstitium and focally associated with a myocyte injury (at the green arrow). H&E, 400x.

Similar articles

Cited by

References

    1. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. Valent P, Klion AD, Horny HP, et al. J Allergy Clin Immunol. 2012;130:607–612. - PMC - PubMed
    1. World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management. Shomali W, Gotlib J. Am J Hematol. 2022;97:129–148. - PubMed
    1. Mechanisms of eosinophilia in the pathogenesis of hypereosinophilic disorders. Ackerman SJ, Bochner BS. Immunol Allergy Clin North Am. 2007;27:357–375. - PMC - PubMed
    1. Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence. Crane MM, Chang CM, Kobayashi MG, Weller PF. J Allergy Clin Immunol. 2010;126:179–181. - PMC - PubMed
    1. Hypereosinophilic syndrome: considerations for the cardiologist. Bondue A, Carpentier C, Roufosse F. Heart. 2022;108:164–171. - PubMed

Publication types

LinkOut - more resources